Get the Stockscreener App
0.95
0.36%
0.0154
Calcimedica Inc stock is traded at $0.95, with a volume of 312.44K.
It is up +0.36% in the last 24 hours and down -8.59% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$0.9654
Open:
$0.9364
24h Volume:
312.44K
Relative Volume:
0.26
Market Cap:
$15.16M
Revenue:
-
Net Income/Loss:
$-19.54M
P/E Ratio:
-0.7268
EPS:
-1.3071
Net Cash Flow:
$-21.18M
1W Performance:
-1.83%
1M Performance:
-8.59%
6M Performance:
-83.03%
1Y Performance:
-39.82%
1-Day Range:
$0.89
$1.0252
1-Week Range:
$0.85
$1.15
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.9594 | 16.27M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.45 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
Form 13D/A CALCIMEDICA For: 30 June By Investing.com - Investing.com Canada
CalciMedica (CALC) insiders add shares via open-market and unit purchases - Stock Titan
Form 4 CalciMedica Inc For: 29 June By Investing.com - Investing.com South Africa
Calcimedica director Fred Middleton acquires $199,999 in stock. - Investing.com
Calcimedica director Fred Middleton acquires $199,999 in stock. By Investing.com - Investing.com Canada
CalciMedica (CALC) chief business officer gets 186,729-share stock award at $0.8033 - Stock Titan
CalciMedica (CALC) insider-affiliated fund buys 248,972 new shares at $0.8033 - Stock Titan
FDA raises no concerns over Auxora safety data, CalciMedica advances trial - MSN
CalciMedica (NASDAQ: CALC) lenders capped at 4.99% ownership after loan amendment - Stock Titan
Key facts: CalciMedica $15M raise; Auxora paused, FDA feedback due Q3 - TradingView
CalciMedica Receives FDA Clearance to Resume Auxora Clinical Trial for Acute Kidney Injury After Safety Review - Minichart
CalciMedica Announces Private Placement Financing for Up to About $49M to Advance Pulmonary Hypertension Program - Moomoo
CalciMedica Advances Auxora After Favorable FDA Safety Review - TipRanks
CalciMedica (Nasdaq: CALC) raises $15M, maps PAH and PH trial plans - Stock Titan
H.C. Wainwright Maintains CalciMedica(CALC.US) With Hold Rating - Moomoo
CalciMedica says FDA allows KOURAGE trial to continue - grafa.com
CalciMedica receives FDA clearance to continue Auxora trial By Investing.com - Investing.com Australia
CalciMedica, Inc. Announces Amendments to Loan and Warrant Agreements with Avenue Venture Opportunities Fund II, L.P – Minichart - Minichart
$CalciMedica (CALC.US)$ - Moomoo
What's Going On With CalciMedica Stock Wednesday?CalciMedica (NASDAQ:CALC) - Benzinga
CalciMedica secures up to $49M private placement financing - Investing.com
CalciMedica receives FDA clearance to continue Auxora trial - Investing.com
CalciMedica: Proceeds Expected to Support Pulmonary Hypertension Strategy, Including Phase 1b POC Study Evaluating Auxora in PAH, With Data Anticipated Mid-2027, and Advancement of Oral CRAC Channel Inhibitor CM5480 to IND Clearance Expecte - Moomoo
CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review - marketscreener.com
CalciMedica to Sell 18.7M Units >CALC - Moomoo
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data - The AI Journal
CalciMedica Entered Into Definitive Securities Purchase Agreement With Leading Healthcare Investors >CALC - Moomoo
CalciMedica Amends Loan, Issues New Equity Warrants - TipRanks
Calcimedica Announces Private Placement Financing For Up To Approximately $49 Million To Advance Pulmonary Hypertension Program - TradingView
Press Release: CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program - Moomoo
CalciMedica Extends $10M Loan, Adds $3M Conversion; Issues New $1.00 Warrants - TradingView
CalciMedica (NASDAQ: CALC) extends Avenue loan and issues new $1.00 warrants - Stock Titan
CalciMedica Inc (CALC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CALC News | CALCIMEDICA INC (NASDAQ:CALC) - ChartMill
CalciMedica Inc (CALC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CalciMedica Inc (CALC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CalciMedica Inc (CALC) Institutional Confidence - TradingKey
CalciMedica Inc (CALC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CalciMedica Inc (CALC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CalciMedica Inc (CALC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CalciMedica Inc (CALC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CalciMedica (CALC) Holds Steady Above $0.83 Support After Nearly Flat SessionPercent Above MA - newsline.com
CalciMedica (CALC) Slips 2.75% as Stock Tests Key Support LevelsVolatility Breakout Picks - newsline.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CALC Q1 2026 Earnings: Surprising Profitability Amid No RevenueHigh Growth Earnings - newsline.com
CALC Stock Chart | CALCIMEDICA INC (NASDAQ:CALC) - ChartMill
CALC Q1 2026 Earnings: Surprise Profit Amid Pre-Revenue Pipeline ProgressPost-Earnings Drift - newsline.com
CalciMedica (CALC) Slips 6%: Support Level Holds Key to RecoveryCTA Positioning - newsline.com
CALCCalciMedica Inc Stock Price and Quote - Finviz
CalciMedica (CALC) Faces Selling Pressure Near Support as Biotech Uncertainty PersistsRevenue Weighted - newsline.com
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 18 '25 |
Buy |
3.07 |
2,500 |
7,675 |
84,150 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 15 '25 |
Buy |
2.68 |
3,400 |
9,105 |
81,650 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 12 '25 |
Buy |
3.12 |
5,000 |
15,600 |
78,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 09 '25 |
Buy |
3.15 |
2,343 |
7,378 |
73,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 28 '25 |
Buy |
2.86 |
9,200 |
26,340 |
70,107 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 29 '25 |
Buy |
2.74 |
800 |
2,192 |
70,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 21 '25 |
Buy |
2.79 |
3,508 |
9,797 |
60,907 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Option Exercise |
1.53 |
15,000 |
22,950 |
179,706 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 20 '25 |
Buy |
2.72 |
2,000 |
5,440 |
57,399 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 19 '25 |
Buy |
2.79 |
1,000 |
2,790 |
55,399 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):